There is one clinical trial.
The purpose of this study is to reduce melanoma mortality by improving early detection of melanoma with skin self-examination (SSE) among people who self-identify as being at risk and seek care for a concerning mole. Because women are more likely than men to perform SSE, women who are engaged in health promotion by having a recent screening mammogram are the focus of this research. Self-management of melanoma detection with SSE depends on ready access to dermatologists when a concerning mole is detected. In March 2020, the Illinois stay at home order (COVID-19) prohibited non-essential health care, including screening mammography and dermatology office-based care, and both are expected to remain limited until fall 2020. This submission explores a) the effectiveness of targeted melanoma detection (TMD) among women, who identify their risk of having a melanoma, learn to perform SSE, and perform SSE, and b) the effectiveness of adhesive patch-based home sample collection for genomic analysis to rule out melanoma in moles identified by women as concerning.
Description: Self-reported performance of SSE, a custom scale with the frequency and extent of SSE is completed in an online monthly survey
Measure: Change in SSE performance Time: 90 daysDescription: Self-reported identification of concerning mole identified by user assigning scores to the border,color and diameter of the mole. A validated scoring system is used to categorize the border, color and diameter as 1 if normal, 2 if not sure, and 3 if abnormal.The sum of the scores indicates if the mole is concerning (sum of 3= benign, stop checking the mole; sum of 4- 7 monitor the mole for change in the next month; sum of 8-9 = concerning mole make an appointment to see a physician.
Measure: Identification of concerning mole Time: 90 daysDescription: The quantity of cells obtained for genomic analysis will be assessed. The results of the genomic analysis will be validated with the pathological findings of the biopsied concerning mole. A Student t test will be performed for the null hypothesis of no difference between the genomic analysis and the pathological finding of melanoma.
Measure: Effectiveness of adhesive patch-based home sample collection for genomic analysis of concerning moles to rule-out melanoma Time: 90 DaysDescription: Self-reported responses to 7 items, each with a 5-point Likert scale (range 7-35) higher score= more anxiety
Measure: Change in skin self-examination anxiety Time: 90 daysDescription: Self-reported responses to 7 items, each with a 5-point Likert scale (range 7-35) higher score = greater confidence.
Measure: Change in confidence performing mole checks Time: 90 daysDescription: Electronic medical record review
Measure: Number of physician visits for concerning moles Time: 5 monthsDescription: Electronic medical record review
Measure: Number of biopsies of concerning moles Time: 5 months